Germany’s Complement Bets On Gene Therapy For Geographic Atrophy
As Series A Raises €72m
Executive Summary
US approval of Apellis's Syfovre has validated the complement approach for treating the advanced stage of age-related macular degeneration but a Munich-headquartered start-up believes its gene therapy will be a more potent and less burdensome alternative.
You may also be interested in...
Finance Watch: Q2 Saw Fewer, But Larger, Venture Capital Deals
Private Company Edition: Fewer biotech companies raised venture capital in the second quarter, but the amount of capital raised was on par with the first quarter. Also, former BMS R&D exec Rupert Vessey joined Flagship Pioneering, two new VC funds emerged and Septerna raised a $150m series B round.
Forbion Will Use New Fund To Rescue Struggling Biotechs
The Netherlands and Germany-based VC firm wants to help out public and private companies who have undervalued late-stage assets and are struggling to raise new funds.
Iveric Bio Building Ophthalmology Commercial Team Ahead Of First Launch
CEO Glenn Sblendorio talked to Scrip about the company's plans to transition into a commercial-stage company after completing an NDA submission for its geographic atrophy drug in December.